B-cell-depletion therapy in systemic autoinmune diseases. Recommendations for use in clinical practice;Tratamiento depletivo de células B en enfermedades autoinmunitarias sistémicas. Recomendaciones de uso en la práctica clínica

Medicina Clinica

Volumn 136, Issue 6, 2011, Pages 257-263

  Ramos Casals, Manuel ^a   Díaz Lagares, Cándido ^a   Khamashta, Munther A ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUTOIMMUNE DISEASE; B CELL DEPLETION THERAPY; CLINICAL PRACTICE; PRACTICE GUIDELINE; SYSTEMIC DISEASE; THERAPY;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOCYTE DEPLETION; RECURRENCE;

EID: 79952310444     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2010.03.016     Document Type: Article

References (60)

1. F.J. García Hernández, C. Ocaa Medina, R. González Len, R. Garrido Rasco, R. Colorado Bonilla, and M.J. Castillo Palma Utilidad del rituximab en el tratamiento de pacientes con enfermedades sistémicas autoinmunitarias Med Clin (Barc) 128 2007 458 462
2. D. Albert, J. Dunham, S. Khan, J. Stansberry, S. Kolasinski, and D. Tsai Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus Ann Rheum Dis 67 2008 1724 1731
3. P.M. Aries, B. Hellmich, J. Voswinkel, M. Both, B. Nlle, and K. Holl-Ulrich Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations Ann Rheum Dis 65 2006 853 858
4. G. Basse, D. Ribes, N. Kamar, M. Mehrenberger, F. Sallusto, and L. Esposito Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients Transplant Proc 38 2006 2308 2310 (Pubitemid 46068544)
5. J.N. Boletis, S. Marinaki, C. Skalioti, S.S. Lionaki, A. Iniotaki, and P.P. Sfikakis Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: A long-term prospective study Nephrol Dial Transplant 24 2009 2157 2160
6. R. Cavallo, D. Roccatello, E. Menegatti, C. Naretto, F. Napoli, and S. Baldovino Rituximab in cryoglobulinemic peripheral neuropathy J Neurol 256 2009 1076 1082
7. L. Chung, M.C. Genovese, and D.F. Fiorentino A pilot trial of rituximab in the treatment of patients with dermatomyositis Arch Dermatol 143 2007 763 767 (Pubitemid 46955736)
8. S. Dass, S.J. Bowman, E.M. Vital, K. Ikeda, C.T. Pease, and J. Hamburger Reduction of fatigue in Sjgren syndrome with rituximab: Results of a randomised, double-blind, placebo-controlled pilot study Ann Rheum Dis 67 2008 1541 1544
9. V. Devauchelle-Pensec, Y. Pennec, J. Morvan, J.O. Pers, C. Daridon, and S. Jousse-Joulin Improvement of Sjgren's syndrome after two infusions of rituximab (anti-CD20) Arthritis Rheum 57 2007 310 317 (Pubitemid 47164095)
10. P. Eriksson Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab J Intern Med 257 2005 540 548 (Pubitemid 40776514)
11. J.Z. Gillis, M. Dall'era, A. Gross, J. Yazdany, and J. Davis Six refractory lupus patients treated with rituximab: A case series Arthritis Rheum 57 2007 538 542 (Pubitemid 46682546)
12. J.E. Gottenberg, L. Guillevin, O. Lambotte, B. Combe, Y. Allanore, A. Cantagrel Club Rheumatismes et Inflammation (CRI) Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases Ann Rheum Dis 64 2005 913 920 (Pubitemid 40733918)
13. J.C. Henes, J. Fritz, S. Koch, R. Klein, M. Horger, and T. Risler Rituximab for treatment-resistant extensive Wegener's granulomatosisadditive effects of a maintenance treatment with leflunomide Clin Rheumatol 26 2007 1711 1715
14. R.B. Jones, A.J. Ferraro, A.N. Chaudhry, P. Brogan, A.D. Salama, and K.G. Smith A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis Arthritis Rheum 60 2009 2156 2168
15. T. Jnsdttir, I. Gunnarsson, A. Risselada, E.W. Henriksson, L. Klareskog, and R.F. Van Vollenhoven Treatment of refractory SLE with rituximab plus cyclophosphamide: Clinical effects, serological changes, and predictors of response Ann Rheum Dis 67 2008 330 334 (Pubitemid 351281266)
16. K.A. Keogh, S.R. Ytterberg, F.C. Fervenza, K.A. Carlson, D.R. Schroeder, and U. Specks Rituximab for refractory Wegener's granulomatosis: Report of a prospective, open-label pilot trial Am J Respir Crit Care Med 173 2006 180 187 (Pubitemid 43187890)
17. R. Lafyatis, E. Kissin, M. York, G. Farina, K. Viger, and M.J. Fritzler B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis Arthritis Rheum 60 2009 578 583
18. G. Leroux, N. Costedoat-Chalumeau, B. Brihaye, J. Cohen-Bittan, Z. Amoura, and J. Haroche Treatment of relapsing polychondritis with rituximab: A retrospective study of nine patients Arthritis Rheum 61 2009 577 582
19. T.D. Levine Rituximab in the treatment of dermatomyositis: An open-label pilot study Arthritis Rheum 52 2005 601 607 (Pubitemid 40216325)
20. E.K. Li, L.S. Tam, T.Y. Zhu, M. Li, C.L. Kwok, and T.K. Li Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis? Rheumatology (Oxford) 48 2009 892 898
21. C. Lindholm, K. Brjesson-Asp, K. Zendjanchi, A.C. Sundqvist, A. Tarkowski, and M. Bokarewa Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus J Rheumatol 35 2008 826 833 (Pubitemid 351747123)
22. R.J. Looney, J.H. Anolik, D. Campbell, R.E. Felgar, F. Young, and L.J. Arend B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab Arthritis Rheum 50 2004 2580 2589 (Pubitemid 39062719)
23. S. Lovric, U. Erdbruegger, P. Kmpers, A. Woywodt, C. Koenecke, and H. Wedemeyer Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: A single-centre experience with 15 patients Nephrol Dial Transplant 24 2009 179 185
24. T.Y. Lu, K.P. Ng, G. Cambridge, M.J. Leandro, J.C. Edwards, and M. Ehrenstein A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: The first fifty patients Arthritis Rheum 61 2009 482 487
25. M. Martínez del Pero, A. Chaudhry, R.B. Jones, P. Sivasothy, P. Jani, and D. Jayne B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: A cohort study Clin Otolaryngol 34 2009 328 335
26. C. Melander, M. Salle, P. Trolliet, S. Candon, X. Belenfant, and E. Daugas Rituximab in severe lupus nephritis: Early B-cell depletion affects long-term renal outcome Clin J Am Soc Nephrol 4 2009 579 587
27. R. Pepper, M. Griffith, C. Kirwan, J. Levy, D. Taube, and C. Pusey Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids Nephrol Dial Transplant 2009 [Epub ahead of print]
28. J. Pijpe, G.W. Van Imhoff, F.K. Spijkervet, J.L. Roodenburg, G.J. Wolbink, and K. Mansour Rituximab treatment in patients with primary Sjgren's syndrome: An open-label phase II study Arthritis Rheum 52 2005 2740 2750 (Pubitemid 41369102)
29. L. Quartuccio, G. Soardo, G. Romano, F. Zaja, C.A. Scott, and G. De Marchi Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: Efficacy and safety in the absence of steroids Rheumatology (Oxford) 45 2006 842 846 (Pubitemid 43985372)
30. J.A. Reynolds, V. Toescu, C.S. Yee, A. Prabu, D. Situnayake, and C. Gordon Effects of rituximab on resistant SLE disease including lung involvement Lupus 18 2009 67 73
31. D. Roccatello, S. Baldovino, D. Rossi, M. Mansouri, C. Naretto, and M. Gennaro Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis Nephrol Dial Transplant 19 2004 3054 3061 (Pubitemid 40057628)
32. D. Sansonno, V. De Re, G. Lauletta, F.A. Tucci, M. Boiocchi, and F. Dammacco Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20 Blood 101 2003 3818 3826 (Pubitemid 36857852)
33. P. Seo, U. Specks, and K.A. Keogh Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations J Rheumatol 35 2008 2017 2023
34. R. Seror, C. Sordet, L. Guillevin, E. Hachulla, C. Masson, and M. Ittah Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjgren's syndrome Ann Rheum Dis 66 2007 351 357 (Pubitemid 46579637)
35. P.P. Sfikakis, J.N. Boletis, S. Lionaki, V. Vigklis, K.G. Fragiadaki, and A. Iniotaki Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: An open-label trial Arthritis Rheum 52 2005 501 513 (Pubitemid 40216314)
36. K.G. Smith, R.B. Jones, S.M. Burns, and D.R. Jayne Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment Arthritis Rheum 54 2006 2970 2982 (Pubitemid 44497778)
37. V.P. Smith, J.T. Van Praet, B.R. Vandooren, B. Vander Cruyssen, J.M. Naeyaert, and S. Decuman Rituximab in diffuse cutaneous systemic sclerosis: An open-label clinical and histopathological study Ann Rheum Dis 2008 [Epub ahead of print]
38. R. Stasi, E. Stipa, G. Del Poeta, S. Amadori, A.C. Newland, and D. Provan Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab Rheumatology (Oxford) 45 2006 1432 1436 (Pubitemid 44605482)
39. S.M. Sultan, K.P. Ng, J.C. Edwards, D.A. Isenberg, and G. Cambridge Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy Clin Exp Rheumatol 26 2008 887 893
40. J.A. Sutter, J. Kwan-Morley, J. Dunham, Y.Z. Du, M. Kamoun, and D. Albert A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): Factors associated with B lymphocyte recovery Clin Immunol 126 2008 282 290
41. Y. Tamimoto, T. Horiuchi, H. Tsukamoto, J. Otsuka, H. Mitoma, and Y. Kimoto A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: Immunological analysis of B cells, T cells and cytokines Rheumatology (Oxford) 47 2008 821 827 (Pubitemid 351796367)
42. Y. Tanaka, K. Yamamoto, T. Takeuchi, N. Nishimoto, N. Miyasaka, and T. Sumida A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus Mod Rheumatol 17 2007 191 197 (Pubitemid 46929903)
43. S.R. Taylor, A.D. Salama, L. Joshi, C.D. Pusey, and S.L. Lightman Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis Arthritis Rheum 60 2009 1540 1547
44. B. Terrier, D. Saadoun, D. Sne, J. Sellam, L. Prard, and B. Coppr Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: A long-term followup study of thirty-two patients Arthritis Rheum 60 2009 2531 2540
45. M. Tokunaga, K. Saito, D. Kawabata, Y. Imura, T. Fujii, and S. Nakayamada Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system Ann Rheum Dis 66 2007 470 475 (Pubitemid 46580466)
46. M. Vigna-Pérez, B. Hernández-Castro, O. Paredes-Saharopulos, D. Portales-Pérez, L. Baranda, and C. Abud-Mendoza Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: A pilot study Arthritis Res Ther 8 2006 R83
47. M. Visentini, M. Granata, M.L. Veneziano, F. Borghese, M. Carlesimo, and F. Pimpinelli Efficacy of low-dose rituximab for mixed cryoglobulinemia Clin Immunol 125 2007 30 33 (Pubitemid 47374540)
48. F. Zaja, S. De Vita, C. Mazzaro, S. Sacco, D. Damiani, and G. De Marchi Efficacy and safety of rituximab in type II mixed cryoglobulinemia Blood 101 2003 3827 3834 (Pubitemid 36857853)
49. A.M. Jacobi, D.M. Goldenberg, F. Hiepe, A. Radbruch, G.R. Burmester, and T. Drner Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls Ann Rheum Dis 67 2008 450 457 (Pubitemid 351498422)
50. S.D. Steinfeld, L. Tant, G.R. Burmester, N.K. Teoh, W.A. Wegener, and D.M. Goldenberg Epratuzumab (humanised anti-CD22 antibody) in primary Sjgren's syndrome: An open-label phase I/II study Arthritis Res Ther 8 2006 R129
51. Guas de Prctica Clínica SEMI. "Recomendaciones sobre el uso off-label de rituximab en enfermedades autoinmunes sistémicas" [consultado 31/1/2010]. Disponible en: http://www.fesemi.org/grupos/otros/ noticias/index.php
52. H. Tahir, J. Rohrer, A. Bhatia, W.A. Wegener, and D.A. Isenberg Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab Rheumatology (Oxford) 44 2005 561 562 (Pubitemid 41511154)
53. S. Aksoy, H. Harputluoglu, S. Kilickap, D.S. Dede, O. Dizdar, and K. Altundag Rituximab-related viral infections in lymphoma patients Leuk Lymphoma 48 2007 1307 1312 (Pubitemid 47079357)
54. L.H. Calabrese, E.S. Molloy, D. Huang, and R.M. Ransohoff Progressive multifocal leukoencephalopathy in rheumatic diseases: Evolving clinical and pathologic patterns of disease Arthritis Rheum 56 2007 2116 2128 (Pubitemid 47173558)
55. K.R. Carson, A.M. Evens, E.A. Richey, T.M. Habermann, D. Focosi, and J.F. Seymour Progressive multifocal laucoencephalopathy following rituximab therapy in HIV negative patients: A report of 57 cases from the research on Adverse Event and Reports (RADAR) project Blood 113 2009 4834 4840
56. M. Ramos-Casals, R. Pérez-Álvarez, C. Diaz-Lagares, M.J. Cuadrado, M.A. Khamashta BIOGEAS Study Group Autoimmune diseases induced by biological agents A double-edged sword? Autoimmun Rev 2009 [Epub ahead of print]
57. X. Mariette, F. Tubach, H. Bagheri, M. Bardet, J.M. Berthelot, and P. Gaudin Lymphoma in patients treated with anti-TNF. Results of the 3-year prospective French RATIO registry Ann Rheum Dis 2009 [Epub ahead of print]
58. M. Ramos-Casals, C. Díaz-Lagares, and M.A. Khamashta Rituximab and lupus: Good in real life, bad in controlled trials. Comment on the article by Lu et al Arthritis Rheum 61 2009 1281 1282
59. M. Petri, R. Furie, J. Merrill, D.J. Wallace, E.M. Ginzler, and W. Stohl Four-year experience of belimumab, a BLyS-Specific inhibitor, in systemic lupus erythematosus Arthritis Rheum 60 2009 S774
60. E.A. Rossi, D.M. Goldenberg, T.M. Cardillo, R. Stein, and C.H. Chang Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma Blood 113 2009 6161 6171